State Street
DNTH icon

State Street’s Dianthus Therapeutics DNTH Stock Holding History

State Street’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230M Buy
2,357,440
+958,527
+69% +$83.7M 0.01% 971
2026
Q1 		$117M Sell
1,398,913
-108,706
-7% -$6.3M ﹤0.01% 1289
2025
Q4 		$62.1M Buy
1,507,619
+836,571
+125% +$32.4M ﹤0.01% 1622
2025
Q3 		$26.4M Sell
671,048
-149,089
-18% -$3.81M ﹤0.01% 2092
2025
Q2 		$15.3M Buy
820,137
+60,458
+8% +$1.13M ﹤0.01% 2333
2025
Q1 		$13.8M Sell
759,679
-59,164
-7% -$1.3M ﹤0.01% 2331
2024
Q4 		$17.9M Sell
818,843
-2,288
-0.3% -$58.8K ﹤0.01% 2282
2024
Q3 		$22.5M Buy
821,131
+413,425
+101% +$11.5M ﹤0.01% 2140
2024
Q2 		$10.6M Buy
407,706
+387,308
+1,899% +$9.31M ﹤0.01% 2531
2024
Q1 		$612K Buy
+20,398
New +$443K ﹤0.01% 3595
2023
Q3 		– Sell
-8,700
Closed -$106K – 4571
2023
Q2 		$106K Hold
8,700
– – ﹤0.01% 4226
2023
Q1 		$111K Hold
8,700
– – ﹤0.01% 4292
2022
Q4 		$55K Hold
8,700
– – ﹤0.01% 4539
2022
Q3 		$196K Buy
8,700
+781
+10% +$21.4K ﹤0.01% 4150
2022
Q2 		$152K Sell
7,919
-26,591
-77% -$657K ﹤0.01% 4332
2022
Q1 		$1.6M Sell
34,510
-1,595
-4% -$87.1K ﹤0.01% 3651
2021
Q4 		$2.56M Buy
36,105
+2,575
+8% +$259K ﹤0.01% 3566
2021
Q3 		$3.91M Buy
33,530
+4,815
+17% +$561K ﹤0.01% 3356
2021
Q2 		$4.49M Buy
28,715
+6,090
+27% +$1.12M ﹤0.01% 3300
2021
Q1 		$4.29M Buy
22,625
+96
+0.4% +$16.2K ﹤0.01% 3113
2020
Q4 		$2.83M Buy
22,529
+369
+2% +$41.8K ﹤0.01% 3226
2020
Q3 		$2.41M Sell
22,160
-471
-2% -$55.8K ﹤0.01% 3119
2020
Q2 		$2.72M Buy
22,631
+508
+2% +$71.6K ﹤0.01% 3058
2020
Q1 		$2.22M Sell
22,123
-597
-3% -$111K ﹤0.01% 3019
2019
Q4 		$5.51M Buy
22,720
+1,961
+9% +$366K ﹤0.01% 2804
2019
Q3 		$3.41M Buy
20,759
+3,464
+20% +$658K ﹤0.01% 2982
2019
Q2 		$4.08M Buy
17,295
+7,777
+82% +$1.92M ﹤0.01% 2937
2019
Q1 		$2.51M Buy
9,518
+8,112
+577% +$1.4M ﹤0.01% 3060
2018
Q4 		$128K Buy
+1,406
New +$192K ﹤0.01% 3616

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

State Street's DNTH Position: Q2 2026 in Review

State Street increased its Dianthus Therapeutics (DNTH) stake by 69% in Q2 2026, buying an estimated $83.7M and bringing the position to 2,357,440 shares worth $230M. The position accounts for 0.01% of the portfolio, ranked #971.

State Street first reported a position in DNTH in Q4 2018 and has held it in 29 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • State Street held 2,357,440 shares of Dianthus Therapeutics worth $230M as of Q2 2026.
  • State Street bought 958,527 Dianthus Therapeutics shares in Q2 2026, an estimated $83.7M.
  • Dianthus Therapeutics made up 0.01% of State Street's portfolio in Q2 2026, its #971 holding.
  • State Street first reported a position in Dianthus Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.